3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
3
Plasma cell
1
Gynecologic
1
Breast
1
Conditions
Multiple Myeloma
32
Neoplasms, Plasma Cell
6
Recurrence
4
Lymphoma
4
Leukemia
3
Hodgkin Disease
3
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Plasma Cell
2
Hematologic Neoplasms
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Participation
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
liposomal doxorubicin
1
Thalidomide
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AIDS-related Kaposi sarcoma
×
liposomal doxorubicin
×
Plasma cell
×
Clear all
NCT05567601
2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1
Completed
36 enrolled